Completed PHASE1 INTERVENTIONAL 6-arm NCT00400660

A First Time In Human Study To Assess The Compound GSK615915

First Time in Human, Single Dose and Repeat Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of GSK615915

Sponsor: GlaxoSmithKline

Conditions Bronchospasm

Interventions GSK615915A Placebo

Updated 6 times since 2017 Last updated: Sep 27, 2017 Started: Nov 23, 2005 Primary completion: Jul 3, 2006 Completion: Jul 3, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Bronchospasm, this trial is completed. The trial is conducted by GlaxoSmithKline and has accumulated 6 data snapshots since 2005. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Oct 2017 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Oct 2017 [monthly]

Completed PHASE1

First recorded

Nov 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline

Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Edinburgh, United Kingdom